Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Rumi Kurihara"'
Publikováno v:
Medicina, Vol 60, Iss 6, p 991 (2024)
Bacground and Objectives: The objective of this study is to investigate how different therapies modulating insulin resistance, either causally or consequently, affect metabolic parameters in treatment-naïve subjects with T2DM. Subjects and Methods:
Externí odkaz:
https://doaj.org/article/5ee7b3cd4b0545628858a929c667b6ad
Publikováno v:
European Journal of Clinical Pharmacology.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4978f7a29d687ebd59ae0cf0a05f848a
https://doi.org/10.1007/s00228-023-03506-3
https://doi.org/10.1007/s00228-023-03506-3
Publikováno v:
Drug Research.
The objective of this study is to investigate the link between the baseline/changes of body weight and those of diabetic parameters during treatment with an SGLT-2 inhibitor. Drug naïve subjects with T2DM received canagliflozin monotherapy for 3 mon
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9768f8ffd70b612ae607bf288c5d32d4
https://doi.org/10.1055/a-2007-1893
https://doi.org/10.1055/a-2007-1893
Objectives This work is to investigate the regulation of adipose tissues insulin resistance with DPP-4 inhibitors in relation to other diabetic parameters in treatment naïve subjects with T2DM. Methods The subjects received alogliptin 12.5–25 mg/d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cca2d2865c78ace946ba4110db35e31e
https://doi.org/10.21203/rs.3.rs-2482154/v1
https://doi.org/10.21203/rs.3.rs-2482154/v1
Publikováno v:
Drug Research. 71:157-165
The aim of this study is to investigate whether sitagliptin can be used as an initial drug for T2DM and to evaluate its effects on metabolic parameters in relation to its glycemic efficacies. The subjects received 25−50 mg/day sitagliptin monothera
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::78e8d8e98b02d89270e70cb36833e5e1
https://doi.org/10.1055/a-1304-3430
https://doi.org/10.1055/a-1304-3430
Publikováno v:
Hospital Practice. 48:68-74
The aim of this study is to investigate the correlations between the changes of body weight and metabolic parameters during canagliflozin treatment.Drug naïve subjects with T2DM (n = 84) received canagliflozin monotherapy for 3 months. The subjects
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::15d28e06fe800739f6e18d84ee98ee1d
https://doi.org/10.1080/21548331.2020.1732098
https://doi.org/10.1080/21548331.2020.1732098
Publikováno v:
Drug research. 72(2)
The objective of this study is to investigate the regulations of FFA with canagliflozin in relation to metabolic parameters. Drug naïve subjects with T2DM were administered 50–100 mg/day canagliflozin monotherapy (n=70) for 3 months. Significant c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3a0bd2f4f39a8c3e0bd2ec2a8dde2ab3
https://pubmed.ncbi.nlm.nih.gov/34729722
https://pubmed.ncbi.nlm.nih.gov/34729722
Publikováno v:
International journal of clinical practiceREFERENCES. 75(12)
OBJECTIVES The aim of this study was to investigate the differential regulation of metabolic parameters between pioglitazone and canagliflozin in relation to their glycaemic efficacies. METHODS Drug-naive subjects with T2DM received pioglitazone 15-3
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dd7f96bf2e92ca4c3e487a7e906b85bb
https://pubmed.ncbi.nlm.nih.gov/34551185
https://pubmed.ncbi.nlm.nih.gov/34551185